PL2542576T3 - Sposoby badań przesiewowych przeciwciał - Google Patents

Sposoby badań przesiewowych przeciwciał

Info

Publication number
PL2542576T3
PL2542576T3 PL11751155.0T PL11751155T PL2542576T3 PL 2542576 T3 PL2542576 T3 PL 2542576T3 PL 11751155 T PL11751155 T PL 11751155T PL 2542576 T3 PL2542576 T3 PL 2542576T3
Authority
PL
Poland
Prior art keywords
methods
screening antibodies
antibodies
screening
Prior art date
Application number
PL11751155.0T
Other languages
English (en)
Inventor
Robert Lyon
Dennis Benjamin
Maureen Ryan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2542576T3 publication Critical patent/PL2542576T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11751155.0T 2010-03-02 2011-02-28 Sposoby badań przesiewowych przeciwciał PL2542576T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30972510P 2010-03-02 2010-03-02
US32343310P 2010-04-13 2010-04-13

Publications (1)

Publication Number Publication Date
PL2542576T3 true PL2542576T3 (pl) 2016-10-31

Family

ID=44542524

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751155.0T PL2542576T3 (pl) 2010-03-02 2011-02-28 Sposoby badań przesiewowych przeciwciał

Country Status (10)

Country Link
US (2) US9725500B2 (pl)
EP (1) EP2542576B1 (pl)
JP (5) JP5797210B2 (pl)
CN (1) CN102858798B (pl)
CA (1) CA2788289C (pl)
DK (1) DK2542576T3 (pl)
ES (1) ES2581314T3 (pl)
PL (1) PL2542576T3 (pl)
PT (1) PT2542576T (pl)
WO (1) WO2011109308A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
WO2011109308A1 (en) * 2010-03-02 2011-09-09 Seattle Genetics, Inc. Methods for screening antibodies
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2013155634A1 (en) 2012-04-19 2013-10-24 Jiaqi Wu Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) * 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
GB2513405A (en) * 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
SG10202102467RA (en) 2014-07-24 2021-04-29 Genentech Inc Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US20020197694A1 (en) 2001-06-20 2002-12-26 Weiping Shao Conjugates of reduced antibodies and biomolecules
HU230155B1 (hu) * 2001-07-16 2015-09-28 Janssen Pharmaceutica N.V. Javított eljárás benzimidazol típusú vegyületek előállítására
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20030232386A1 (en) * 2002-06-17 2003-12-18 Shah Dinesh O. Assay conjugate and uses thereof
ES2369542T3 (es) * 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US20040038331A1 (en) 2002-08-23 2004-02-26 Reddy M. Parameswara Solid phase synthesis of biomolecule conjugates
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
CN109045307A (zh) * 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
US20090226465A1 (en) 2005-10-31 2009-09-10 Jackson David Y Macrocyclic depsipeptide antibody-drug conjugates and methods
CN101490088B (zh) * 2006-06-22 2015-04-08 健泰科生物技术公司 用于靶向hepsin的方法和组合物
PT2845866T (pt) * 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
US20080233660A1 (en) 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2011005818A1 (en) 2009-07-08 2011-01-13 Bio-Rad Laboratories, Inc. Purification of monoclonal antibodies
WO2011109308A1 (en) * 2010-03-02 2011-09-09 Seattle Genetics, Inc. Methods for screening antibodies

Also Published As

Publication number Publication date
US9725500B2 (en) 2017-08-08
JP2015227891A (ja) 2015-12-17
JP2018076386A (ja) 2018-05-17
JP2013521498A (ja) 2013-06-10
WO2011109308A1 (en) 2011-09-09
EP2542576B1 (en) 2016-04-20
JP6291540B2 (ja) 2018-03-14
PT2542576T (pt) 2016-07-14
CA2788289C (en) 2018-08-21
CN102858798A (zh) 2013-01-02
US20170298118A1 (en) 2017-10-19
HK1180345A1 (zh) 2013-10-18
JP2016216502A (ja) 2016-12-22
JP2019167339A (ja) 2019-10-03
DK2542576T3 (en) 2016-08-01
EP2542576A4 (en) 2013-09-04
US20120322686A1 (en) 2012-12-20
CA2788289A1 (en) 2011-09-09
ES2581314T3 (es) 2016-09-05
EP2542576A1 (en) 2013-01-09
JP6813928B2 (ja) 2021-01-13
JP5998261B2 (ja) 2016-09-28
JP6505882B2 (ja) 2019-04-24
JP5797210B2 (ja) 2015-10-21
CN102858798B (zh) 2015-06-17

Similar Documents

Publication Publication Date Title
PT2542576T (pt) Métodos para rastreio de anticorpos
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
ZA201302459B (en) Antibodies
IL249501B (en) A process for creating antibodies
IL220404A (en) Antiseptic antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
PT2536764T (pt) Anticorpos humanizados anti-cd28
GB201020738D0 (en) Antibodies
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
EP2558587A4 (en) METHOD FOR DISPLAYING ANTIBODIES
IL222533A0 (en) Methods for detecting antibodies
PL3202789T3 (pl) Przeciwciała anty-vla-4
GB201002238D0 (en) Antibodies
GB201120317D0 (en) Screening method
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201013373D0 (en) Screening apparatus
GB201015416D0 (en) Screening method
GB201015419D0 (en) Screening method
GB201006496D0 (en) Screening method
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies
GB201105572D0 (en) Screening method-III